Form 8-K - Current report:
SEC Accession No. 0000950170-23-032425
Filing Date
2023-07-11
Accepted
2023-07-10 20:08:58
Documents
12
Period of Report
2023-07-10
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K reta-20230710.htm   iXBRL 8-K 54890
  Complete submission text file 0000950170-23-032425.txt   171626

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT reta-20230710_lab.xml EX-101.LAB 13937
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT reta-20230710.xsd EX-101.SCH 2461
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT reta-20230710_pre.xml EX-101.PRE 10998
6 EXTRACTED XBRL INSTANCE DOCUMENT reta-20230710_htm.xml XML 4530
Mailing Address 5320 LEGACY DRIVE PLANO TX 75024
Business Address 5320 LEGACY DRIVE PLANO TX 75024 972-865-2219
REATA PHARMACEUTICALS INC (Filer) CIK: 0001358762 (see all company filings)

EIN.: 113651945 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37785 | Film No.: 231080979
SIC: 2834 Pharmaceutical Preparations